Generic Drugs Market By Brand (Pure generic drugs, Branded generic drugs), By Therapeutic Application (Central nervous system (CNS), Cardiovascular, Dermatology, Oncology, Respiratory), Industry Trends, Estimation & Forecast, 2018-2025

September 2018

 Pages: 184

 ERC 9007


Generic Drugs Market is expected to grow with a CAGR of 8% during the forecast period of 2018 to 2025.

Generic drugs are pharmacologically equivalent drugs to the patented ones, containing same active pharmaceutical ingredient, but available at reduced costs in comparison to the patented drugs, owing to the absence of R&D as well as novel drug development costs. Increasing number of patent expiration of branded drugs is one of the major reasons which is stimulating the market growth. This is because patent expirations allow the generic drug manufacturers to enter the market with bioequivalent drugs. For example, generic imatinib by Sun Pharma is priced 30% below the branded drug’s price. Apart from that, various government initiatives to bring more generic drugs in the market is also boosting the market growth. The Hatch-Waxman Act has made the entry of the generic drugs in the market easier by imposition of Abbreviated New Drug Applications (ANDA), which demands only the requirement of bioequivalence of the generic version with the patented drug.

In addition, an increasing prevalence of chronic diseases such as cancer and tuberculosis is also a major catalyst which is amplifying the market growth. The National Institute of Cancer Prevention and Research has estimated that there are around 2.5 million people in India, who are living with cancer. However, it has been witnessed that there is still an existence of skeptical thinking among some doctors and patients regarding the usage of clinically equivalent generic drugs over the branded drugs. This makes the physicians provide “dispense as written” prescriptions to the patients, where pharmacists can only dispense the written branded drug and no other alternative drug, which eventually acts as a hindrance for the market growth.

In the very market, the key players compete on the basis of the premium launch of their generic version of original drug, as the launch time of generic drugs has a high influence on the adoption of that particular drug. Teva Pharmaceutical Industries, Ltd has recently announced the launch of generic Uceris®, extended-release tablets, 9 mg, in the U.S. which will gradually witness an increased adoption in the near future.

The report provides detailed qualitative and quantitative analysis of the Generic Drugs market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely brand and therapeutic Application in each of the major regions.

Generic Drugs Market Player Analysis -

The report presents detailed analysis of major players operating in Generic Drugs market. Few of them include Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Teva Pharmaceutical Industries, Ltd., Sandoz International GmbH, Dr. Reddy’s Laboratories, Apotex, Inc., Par Pharmaceutical, Inc., Hospira, Inc., Watson Pharmaceuticals, Ltd. and others. A detailed coverage on these market players with information on their revenue from Generic Drugs business, market share, gross margin and their growth strategies have been provided in the report.

Market Segmentation

Generic Drugs market is segmented on the basis of type, application and geography. By brand, the market is segmented into pure generic drugs, and branded generic drugs. On the basis of therapeutic application, the market is categorized as central nervous system (CNS), cardiovascular, dermatology, oncology, respiratory, and others. Geographical coverage has been provided for each of the major regions including North America, Europe, Asia-Pacific, South America and Rest of the World.

Generic Drugs Market Segmentation

By Brand
• Pure generic drugs
• Branded generic drugs

By Therapeutic Application
• Central nervous system (CNS)
• Cardiovascular
• Dermatology
• Oncology
• Respiratory
• Others

By geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o France
o Germany
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o Korea
o Rest of APAC
• South America
o Brazil
o Rest of South America
• Rest of the World
o Middle East
o Africa

Generic Drugs Market Key Players

• Ranbaxy Laboratories, Ltd
• Actavis
• Mylan, Inc.
• Teva Pharmaceutical Industries, Ltd.
• Sandoz International GmbH
• Dr. Reddy’s Laboratories
• Apotex, Inc.
• Par Pharmaceutical, Inc.
• Hospira, Inc.
• Watson Pharmaceuticals, Ltd.
• Others

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

    • What was the market size of the Generic Drugs Market in 2018 and the expected market size by 2025, along with the growth rate?
    • An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
    • Which are the largest revenue generating products, services or regions and their comparative growth rate?
    • Which technology is in trend and how would it evolve during the forecast period (2018 - 2025)?
    • Which are the leading companies in the Generic Drugs Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!